Johnson & Johnson (JNJ) Offering Possible 14.42% Return Over the Next 3 Calendar Days

Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $167.50 short put and a strike $162.50 long put offers a potential 14.42% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $167.50 by expiration. The full premium credit of $0.63 would be kept by the premium seller. The risk of $4.37 would be incurred if the stock dropped below the $162.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 79.32 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

EMA Says Heart Inflammation Likely Linked To mRNA-Based COVID-19 Vaccines
Fri, 09 Jul 2021 18:34:58 +0000
European Medicines Agency (EMA) has established a probable link between heart inflammation and mRNA-based COVID-19 vaccines made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA). The EMA said that heart conditions myocarditis and pericarditis must be listed as possible side effects of the two mRNA vaccines. This included an in-depth review of 145 cases of myocarditis and 138 cases of pericarditis in Europe among people who received BioNTech SE’s (NASDAQ: BNTX) Comirnaty and 19 cases in t

Doctor: I would ‘discourage’ getting booster shot different from the vaccine you received
Fri, 09 Jul 2021 18:22:16 +0000
Dr. Adrian Burrowes, Family Medicine Physician &CFP Physicians Group, CEO,  joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.

Abbott Lays Off Around 400 Employees As COVID-19 Test Demand Evaporates
Fri, 09 Jul 2021 18:21:08 +0000
View more earnings on PFESee more from BenzingaClick here for options trades from BenzingaJohnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative ColitisPfizer, BioNTech Working On COVID-19 Booster Shot Targeting Delta Variant© 2021 Benzinga does not provide investment advice. All rights reserved.

10 Best Dividend Stocks for Long Term
Fri, 09 Jul 2021 17:17:19 +0000
In this article, we will be looking at the 10 best dividend stocks for long term. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Best Dividend Stocks for Long Term. Dividend investing is a strategy that has managed to stick around as long as it has for two […]

Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis
Fri, 09 Jul 2021 16:49:04 +0000
The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced new three-year data from the long-term extension (LTE) of the Stelara (ustekinumab) Phase 3 UNIFI study. Investigators designed the trial to evaluate the safety and efficacy of induction and maintenance doses for the treatment in moderate to severely active ulcerative colitis patients. The study enrolled adults who could not tolerate conventional treatments, such as corticosteroids and immunomodulators or biologics.

Be Sociable, Share!

Related Posts